US Patent Issued to Nkarta on Aug. 26 for "CD19-directed chimeric antigen receptors and uses thereof in immunotherapy" (California Inventors)

ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,398,187, issued on Aug. 26, was assigned to Nkarta Inc. (South San Francisco, Calif.).

"CD19-directed chimeric antigen receptors and uses thereof in immunotherapy" was invented by James Barnaby Trager (Albany, Calif.), Luxuan Guo Buren (San Francisco), Chao Guo (San Francisco), Mira Tohme (San Francisco), Ivan Chan (Millbrae, Calif.) and Alexandra Leida Liana Lazetic (San Jose, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR i...